Lithuania vs New Zealand: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Lithuania
- New Zealand
How they compare
Lithuania currently reports 141.25 deaths against 125.08 deaths in New Zealand, a difference of 16.17 deaths.
That makes Lithuania's figure about 1.1 times New Zealand's.
The two have swapped places 3 times across 35 shared years of data; in 1990 it was New Zealand ahead.
Lithuania ranks 119th and New Zealand ranks 122nd of 157 countries.
New Zealand has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Lithuania | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 31.03 deaths | 31.03 deaths | New Zealand |
| 2000s | 14.47 deaths | 73.33 deaths | 58.86 deaths | New Zealand |
| 2010s | 79.24 deaths | 115.95 deaths | 36.71 deaths | New Zealand |
| 2020s | 128.22 deaths | 130.02 deaths | 1.8 deaths | New Zealand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Lithuania or New Zealand?
- Lithuania, at 141.25 deaths against 125.08 deaths in New Zealand as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Lithuania and New Zealand?
- 16.17 deaths, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and New Zealand?
- 35 years are reported by both, from 1990 to 2024.
- How do Lithuania and New Zealand rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Lithuania ranks 119th and New Zealand ranks 122nd of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.